>> this is my kich b table and also my filing system. the highest component of mankind is private equity. then i started interviewing.

i've learned from doing my interview house leaders make it to the top. >> i asked him how much he waned, he said 250, i said fine, didn't negotiate and did in due diligence. >> i have something i'd like to sell. david: and how they staythere you don't feel inadequate now because you're only the second wealthiest man in the world, right? one of the most transformative drug on the market is anti-obesity drugs. one they have leading manufacturers of those see lie lily. they're now one of the most valuable pharmaceutical companies in the world. i sat down with their c.e.o. to talk about this anti-obesity phenomenon and how it's changing america. let's talk about the phenomenon that's changed the world to some extent this anti-obesity drug. now make sure everybody is on the same page, what see this name of your anti-obesity drug. dave: so the name is zepbounk.

the active ingredient is zerpeptide. david: who comes up with these names? >> not me. we can't have name taos close to each other because of mistakes, can't have drugs that say what they do, and can't have drugs that are only good in english. so we end up with strange names. we launched the first anti-obesitied me in 2005. on the cover of our next report is a woman using the drug. the said my diabetes is under control and i'm losing some weight. 2006. the cover of the annual report. we had to improve the medicines to really make them effective for weight loss. one big improvement was to make them weekly, that's a convenience benefit, but even more important, the action of

the medicine flatter, being more consistent through the day and night. when we had it twice and day -- twice a day there were ups and down. one effect of glp-1 medications, they cause nausea and g.i. distress. that's a part of the up and down. when it was weekly, it was dosed higher and the changes were flatter, so made it better for weight loss. david: there's another company in sort of the same business, novo nordisk. they have a similar product. they have a product that does the same thing. one is for obese tirk anti-obesity, one is for diabetes. is there really in difference in terms of the drugs? dave: there are. there's no real difference between the one for die beesby tees and anti-obesity, that's

for insurance purposes. right now, because you just ate lunch your g.i. tract is communicating with the rest of the body, communicating with hormones and protein, saying you've been fed uric need to absorb knew trepts and other things that are see en-- essential to life. what we're doing is boosting some of those signals with these medications. they're boosting the signal that you're full. boosting the signal that you no longer want to eat more. boosting signals that you should absorb nutrients you have consumed. our does that with two different hor moans. one, glp-1 and another g.i.p. osemp i think -- ozempic or semaglutide does similar. david: so it affects the way you feel?

>> as people eat more habitually the you're full signal kicks in later and later. is.does other things too. it make yours stomach fuller. it slows gastric mo tillty. it slow downs nutrient which is is -- seems counterintuitive. but when you eat in the -- when our wanted to absorb all the nutrients out of it. david: there are four different names people should know for the drugs. you have an anti-obesity drug. zepbound. and a diabetes drug. >> mounjaro. >> there was a study that said one-on-one, comparing the two your anti-obesity drug loses weight more rapidly than the other product. >> more rapidly and more. after a year and a half, people

on our drug lost 17 more pounds than wegovy. david: why do people in this country need to lose so much weight? 42% of people in this country are obese. when did that happen? >> it seems to have started in the 1960's, growth in overweight and obesity in the country. accelerated in the 19 80's and 1990's. what are the reasons? how we live is one of them. energy expenditure has to be part of the story. what we need, probably more important reason, not just the quantity, which has risen, modestly, through that period of time, but actually what's in our food has changed. and i think that's also attributed tothis. david: back to the drug. when you realized you can lose weight, did you get the f.d.a. to say it can be prescribed to

lose weight? >> as of last year it's for weight loss. >> to insurance companies reimburse people for the cost of the drugs? >> some do. more should. [laughter] as of today, the federal government actually has a prohibition on reimbursing any of these drugs. which is a problem, i think. although the biden administration just issued advanced rule making to change that. we hope the next administration will continue that process. david: if losing weight makes you healthier why would people who care about insurance reimbursement not insist on paying for this, since it makes you healthier. >> i think in four or five years we'll look back and say yeah that's what should have happened. it's silly we don't pay for what is already known to be a primary contributor to poor health. which is excess body weight. but you know. people have different motives and incentives. maybe your employer has a stronger interest in your long-term health, that's probably why many stepped

forward. and then evidence. our job is to make the evidence prork deuce the evidence that we're not just having people lose weight but losing weight with our medicine causes improved health. we have many studies out this year that are common straiting that. david: to take this medicine you have to inject yourself. why not just go to a pill? >> great idea. we're working on that. the injection, you have to injection because it's a protein. if we orally take proteins your body think it's food and breaks up proteins. so you cannot really take these drugs orally. you have to bypass the g.i. track and go right to the bloodstream. but we are working on a pill. we'll have some data as early as next year for, it's a glp-1 only, single acting, won't be as good -- it'll be about as good as ozempic, we hope. david: some say if you go on this drug you have side effects that are not completely

disde-sierable. is that true? >> all drugs that work have side effect, sometimes untoward effect, we have to warn against those, that's why we do controlled studies and measure them carefully. many people have mild to moderate g.i. distress when we start. we tie trait, start at a low dose and go up slowly. usually by the third or fourth month don't have any more effects at all. david: suppose you take the drug and say i lost weight. happy with my body now. i'm going off the drug. some say it's difficult to not regain the weight? >> that's right. science tells us that there's a reason for that. some people do maintain the weight reduction or stay in that rain only. they have to change a lot about how they live. burn more energy. eat different foods. so we can all try that. i think we should all try that actually. but some people cannot. there's a recent paper in "nature" that told us why.

which is that once you have become obese, your fat cells learn that that's their new state. they defend that state. and so they are wanting more energy. so once we as adults gain weight and have that on for a while it's very, very difficult to reset your thermostat if you would. to reset that level. so for now, we do recommend if they can't -- people cannot maintain weight loss off the drug to go back on the drug and use them chronically.

david: let's talk about eli lilly itself. when was the company started? >> 1876. it was started by a colonel, eli lilly, who served in the civil war. he was a pharmacist by train, led an infantry and artillery company. was a prisoner of war in alabama. he saw firsthand the atrocities of medical care in the civil war. he started the company with a pledge to say, everything that is in this is on the level.

if it's in there you know about it. transparency. that evolved into a company that embraced the scientific method and began to really adopt the methods of the modern industry has which is taking natural products which is what most medicines were in 1876 and refining them into what we think of as medicine now. david: when eli lilly evolved over the years, what were the big products? >> insulin was the birth of the modern company. this was a terrible condition, type 1 diabetes, perp part of commercializing that breakthrough around the world. invented the manufacturing method. that was followed by penicillin so during world war ii, lilly was commissioned as one of the manufacturers of antibiotics for the army. from there we it rated for 40 years antibiotics, including still some have that -- that are used today, including one that's the last line of defense for the worst infections. prozac we're famous for, and now

mown jarreau -- mounjaro and zepbound. david: what are you working on now? >> we use the scientific method to solve problems. we're not interested in nearby problems. we're doing things that we can scale up. we select diseases that are common and tough. alzheimer's. neurodegenerative conditions are the most flightenning people think about. and the science, we've been investing there for 30 years. just launched our first medicine. so now we're getting revenue after 30 years on that proj. we're working on a prevention study for that same medicine which would transform alzheimer's. we think other neurodegenerative conditions are becoming more intractable in science. david: are you concerned about the new administration? have you met with

president-elect trump to talk about your issues? >> health care is always a topic, so then our role in it and medicine affordability is a key area. i think everyone would like the u.s. to have a strong biopharma medicine that insents major medicines like eli lilly does but at the same time we want things to be cheap and accessible for all. that's hard to meet all those things. we were known for the insulin pricing challenges they we had and insulin was overpriced in the u.s. according to the critics. and we were able to bring that price down. i think there are solutions. and by engaging we can find them. david: have you met with anybody in the new administration? >> we had dinner down in florida. david: did they serve up fattening food? >> probably shouldn't say too much about it. it was all you can imagine and a little bit more. [laughter] david: let's talk about your own background. where were you born?

>> i was born in bloomington, indiana, a hoosier by birth. my dad was a grad student at i.u. at the time. we quickly left and moved to california. my mom was from california. i grew up in the bayera. followed in their footsteps and went to purdue back in indiana. david: what did you study there? >> studied business and engineering. went to work for i.b.m. in new york. i joined, the stock was at an all-tight high, when i left it was at an all-him low. they had a tough time in the 1990's. david: you joined eli lilly when? >> i followed my girlfriend, now my wife, who was going to school in indiana. i needed something to do there. i decided to enroll in the m.b.a. program. medicine is a four-year degree, m.b.a. is two, i still needed something to do in indiana so i joined lilly. david: what was your position in the beginning? >> i looked at transactions in

the finance and business development group. great introduction. david: did you ever say i'm going to be the c.e.o. someday? >> not then. i was thinking i'll be here for two years and then off to chicago or san francisco and do something different. but i fell in love with the company. it's an amazing place. it's a very humanistic culture. but yet very rigorous and scientific. so it's demanding, smart people but people are nice to each other. it's the midwest. i fell in love with thing my, what down better than making medicine for people? i worked on a medicine to collaborate and bring into the company for buy diabetes. right as i was leaving that job my mother was diagnosed with diabetes and she was put on that medicine. sort of the point of what we do, just became super salient for me i said this is not a bad way to spend my time. i said to my wife, let's stay here. david: when did you realize you were on track to be the c.e.o.? >> much later.

so i worked in that job. i had some jobs running markets, i ran our canadian business, went to china for 2 1/2 years, rap our chinese business. i was suddenly called back from china by the c.e.o. who was a new c.e.o. he said you need to come run our u.s. business. i said don't you want me to finish the job? he said, you need to come back. that's the point where i was sort of being cultivated for something bigger. david: you have three children? >> yeah, for a while i've had three children. [laughter] yes. they're young adults now. david: ok. all right. any of them interested in weight reduction programs or things like that? not really? >> so my son, he's an a.i. consultant, not so much my daughter is getting a masters in cell biology, interested inned me school. she's thinking about medicine and medical science. we talk a lot about the weight loss drugs my youngest son is a geology student at purdue. david: what do you do for

relaxation, to stay in shape. you're not on one of these drugs, you look very fit, exercise a lot. >> i'm not but i would never hesitate to be on one if i needed it. but the best medicine is prevention. so you know, paying attention to exercise, something i've always cared about. it's a way i reduce stresstoo. i loved run, now i don't run any more but i do other things. i like hiking. love backcountry skiing and the outdoors. play golf. being outside is is where i find both fitness and peace. david: you've had outstanding success at eli lilly. suppose a president of the united states said you should be secretary of h.h.s. or something, what would you say? >> the company as you pointed out is really doing well. but you know, we really have a strong desire to do even more. we're just at the beginning of this weight loss story. you know. right now there's six or seven million americans who are taking these medicines. 110 million with obesity. we need to build more plants.

develop more data. then there's the whole world to cover. ns projected in five years there'll be a billion people on the planet who have obesity. it's going to become a much bigger problem in the developing world than it ever has been in america. we have a lot of work to do to make the biggest impact we have. we had to stop the study, people were losing too much weight to stay in it. at first this was seen as an alarming thing. of course we began to process that as wait a minute this could be somebody very special. david: in the pharmaceutical world the image is not always so wonderful with the public. how do you respond to the idea that drug companies are charging too much, or people say i'm going to cross over to canada and get the same drug for a lower price? >> it's something we want to change and fix. we think what we do is valuable.

for article of history, how health care insurance evolved in this country, people are largely shielded from surgery costs and medicine costs. people think the medicines are a larger part of the health bill because they're exposed to more of that versus services. the second thing is, you know, foreign country, it is true, our prices are lower in those places. we would like to correct that as well. our idea is that basically the cost of a medicine is the cost of the r&d to produce it than the manufacturing. manufacturing costs are similar everywhere. right now there's an imbalance. who covers the r&d cost? we need to correct that. but the answer isn't just lower u.s. to canada's pricing. we wouldn't have a pharmaceutical industry if we did that. we have to raise developed countries what they pay and lower the u.s. i think that's a policy argument we'll hear about soon with the new administration. and we're happy to engage in it.

but we need to do both a the same time. david: when you have drugs that are very, very popular, you have people that make counterfeit or copy cat drugs. what about for this. do you have to worry about counterfeit drugs coming in the same thing? >> it's a terrible problem. i think consumers don't really know the dangers or the difference. today the f.d.a. and the government has allowed this to

sort of grow. of course a weight less medicine that's effective would be a popular thing for people to seek treatment on their own. the data we have is that 0% of the medicines are coming out of china from unapproved, unregulated sources. we recently with borders and customs seized a big patch batch that was shipped in dog food. people then reformulate them and sell them locally inned me spas and other outfits. but you really don't know what's in that vial. we buy and test twhesm find back tier ark plant material, virus, fungus. david: but how much more expensive are your drugs than the counterfeit ones? if somebody wants to use your product, zepbound, how much does it cost a month? >> you can buy it direct from lilly for $399.

david: $3.99? >> no. $399 a month. about $100 a week. that's a sacrifice for. many that's without insurance. with insurance most people pay $25 a month. so that's the importance of insurance. that's why we build bye insurance to shield us from health costs. online ones are as cheap as $100. these are companies that want the benefits of being a drug pane but bear none of the responsibles. david: how many employees does the company have today? >> 44,000. david: and you're headquartered in indianapolis. where do you manufacture your drugs, mostly in the u.s.? mostly overseas? >> mostly in the u.s., a large part in europe as well. in the u.s. we're building a lot of plants right now, mostly to support zepbound and mounjaro. david: when did you realize you were going to become the biggest

drug company in the world? >> it's hard to know. in 2016 i was named incoming c.e.o. that fall one of our scientists in the diabetes group comaild about early results they were receiving from singaporean site we had that was doing a phase 1 study. with the ingredient in zepbound. we had to stop the study, people were losing too much weight to stay in it. at first this was seen as an alarming thing. but of course we began to process that as, wait a minute, this could be something very special. we sped to the next stage of development, phase2. you try to show safety and efficacy in a bigger study. i remember in a, kind of a moment, i was showing my daughter around a college, we were at cal berke lee, standing outside the lawrence hall of science, and i got a phone call. team just got off the plane, got the results. showed that people were losing over 20% body weight in a longer study.

that was in april of 2018. we disclosed those results later that year. you could probably argue a lot of the run-up in lilly was execution from that moment forward. david: did you take the credit for this? are you responsible for this happening? >> of course as c.e.o. you have a role but it would be overstating the role to take credit. the credit goes to scientists. we have a lot of incumbent capability, uh like how do you take a protein like glb-1 and make it into a week-long injection? that's a pharmacology question. we have people that can do that, and people who can do the style trial, we have people who make it every day. it's a giant team sport. david: where do you want to take your company now? you can't find any drug more successful than what you have. you're going to keep promoting this drug? >> within the obesity metabolic health space, there are two things i'm excited ability.

we have mounjaro and zepbound on the market but we have 11 other things aim at the same problem but in different ways. we have a triple-actinged me sip in phase three for people who have higher body weight or more severe weight problems, nine others beyond that. we think this will be a very large segment with many different types of medicines for different conditions. and different situations. people might find themselves in. we're going to exploit that fully. the second thing is, we've talked a lot about cardiokas collar health, these conditions we think about with people being overweight. these medicine, we think, we want to prove, can be useful for other things we don't think of connected to weight. these are often called anti-hedonics, they are reducing the desire cycle. next year you'll see lilly start studies in alcohol abuse, nicotine use, even drug abuse. beyond that we need to make

important medicines for the listening haul. we're an old company, plan to be here another 150 years plus. and i mentioned my excite about about brain health, i think that's the next frontier. >> "the david rubenstein show: peer to peer conversations" is sponsored by --

>> you always look different because you're the first woman, the first brown person, the first person of color to lead a global luxury brand. people don't know what to expect. francine: she's in charge of chanel. the french fashion house known for its icod